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Introduction {#sec005}
============

Esophageal cancer is one of the most common cancers worldwide and has high mortality \[[@pone.0231116.ref001], [@pone.0231116.ref002]\]. The prognosis of patients with esophageal cancer remains poor despite recent improvements in therapy and perioperative management, and 5-year survival rate remains about 20%, even in developed countries \[[@pone.0231116.ref003]\]. One reason for this poor prognosis is that most patients with esophageal cancer are diagnosed at an advanced stage \[[@pone.0231116.ref004]\]. In contrast, early stage esophageal cancer, in particular mucosal cancer is expected cure by endoscopic resection \[[@pone.0231116.ref005], [@pone.0231116.ref006]\]. This substantial discrepancy suggests that a specific diagnostic biomarker could be used for early detection would improvement the prognosis of patients with esophageal cancer. While several biochemical markers have been investigated, including squamous cell carcinoma antigen \[[@pone.0231116.ref007]\], carcinoembryonic antigen \[[@pone.0231116.ref008]\] and, CYFRA 21--1 \[[@pone.0231116.ref009]\], their sensitivity has not proved consistently satisfactory across the various stages of esophageal cancer.

MicroRNA(miR)s are classified as small noncoding RNAs (19--25 nucleotides) which regulate the expression of plural numbers of messenger RNAs \[[@pone.0231116.ref010]--[@pone.0231116.ref012]\]. Cancer cells possess miRs which have particular function in promoting cancer development or minimizing cancer suppression. miRs also exist in the blood stream as inclusions in exosomes. These circulating miRs play a role in intercellular communication in the cancer environment and bring about favorable conditions for cancer invasion and metastasis. Because their expression profiles vary between cancer patients and healthy individuals, circulating miRs can act as powerful biomarkers in the diagnosis of cancer. Indeed, many researchers have reported their usefulness as novel biomarkers for several malignant tumors, including esophageal cancer \[[@pone.0231116.ref013]--[@pone.0231116.ref017]\].

Recent research from deep sequencing represented by the next generation sequencer(NGS) has revealed that miRs are heterogeneous. Isoforms of miR differ slightly from mature miR by base length and sequence and are referred to as isomiR. Although the function of isomiR is not completely understood, they are known to play an important role in cancer development \[[@pone.0231116.ref018], [@pone.0231116.ref019]\]. IsomiRs also exist in the blood with high stability, similarly to mature miRs. We hypothesized that combination of circulating miR and isomiRs detected by NGS might act as novel biomarkers for malignant tumors. To date, however, few studies examined the usefulness of miR/isomiRs from blood samples as cancer biomarkers. Here, we aimed to investigate their application in esophageal squamous cell carcinoma (ESCC) using NGS.

Material and methods {#sec006}
====================

Samples {#sec007}
-------

We prospectively collected serum samples of patients treated for esophageal cancer at Hiroshima University Hospital from January 2010 to July 2018. Before April 2016, samples for patients undergoing surgery were collected only at surgery. Thereafter, samples were collected before treatment from all patients with esophageal cancer, such as at endoscopic resection, chemoradiotherapy, neoadjuvant therapy followed by surgery, and palliative chemotherapy. We used 18 consecutive samples from January 2010 to December 2012, 30 from January 2013 to February 2017, and 18 from March 2017 to July 2018 as the first (1^st^), second (2^nd^), and third (3^rd^) groups, respectively. Healthy control (HC) samples were collected at the same time by our laboratory from individuals who were confirmed not to have a medical history of cancer. Among them, 12, 30, and 18 samples were enrolled in the 1^st^, 2^nd^, and 3^rd^ groups, with consideration to matching sex and age with ESCC patients. [Table 1](#pone.0231116.t001){ref-type="table"} summarizes the characteristics of patients and HCs. All patients were histologically diagnosed with squamous cell carcinoma and staged according to the 8^th^ Edition of the TNM Classification of Malignant Tumors \[[@pone.0231116.ref020]\]. Treatment strategy was determined at our institutions according to clinical stage and patient condition as described previously \[[@pone.0231116.ref021], [@pone.0231116.ref022]\]. Briefly, mucosal cancer was treated with endoscopic resection, submucosal cancer without lymph node metastasis with initial surgery; and respectable advanced cancer with neoadjuvant therapy followed by surgery if overall patient condition was good. Patients who did not wish to undergo surgery or judged unsuitable for resection were treated with definitive chemoradiotherapy, while those with distant metastasis were given palliative chemotherapy.

10.1371/journal.pone.0231116.t001

###### 

**A.** Characteristics in 1^st^ group. **B.** Characteristics in 2^nd^ group. **C.** Characteristics in 3^rd^ group.

![](pone.0231116.t001){#pone.0231116.t001g}

  --------------------- ------------------------ ------------------
  **A**                                          
                        ESCC patients (n = 18)   Control (n = 12)
  Age (y)               68 (54--85)              62 (50--83)
  Sex                                            
  Male                  13 (72.2%)               9 (75%)
  Female                5 (28.8%)                3(25%)
  Smoking                                        
  None                  4 (22.2%)                
  Ex                    6 (33.3%)                
  Current               8 (44.4%)                
  Tumor location                                 
  Ut                    7 (38.9%)                
  Mt                    6 (33.3%)                
  Lt                    3 (16.7%)                
  Ae                    2 (11.1%)                
  Differentiation                                
  Well                  7 (38.9%)                
  Moderate              9 (50%)                  
  Poor                  2 (11.1%)                
  Unknown               0                        
  Clinical Stage                                 
  I                     15 (83.3%)               
  II                    2 (11.1%)                
  III                   1 (5.6%)                 
  IVA                   0                        
  IVB                   0                        
  Treatment                                      
  ESD                   0                        
  Surgery               18 (100%)                
  Neoadjuvant therapy   0                        
  CRT                   0                        
  CT                    0                        
  Pathological Stage                             
  IA                    5 (27.8%)                
  IB                    10 (55.6%)               
  IIA                   1 (5.6%)                 
  IIB                   1 (5.6%)                 
  IIIA                  0                        
  IIIB                  1 (5.6%)                 
  IVA                   0                        
  IVB                   0                        
  **B**                                          
                        ESCC patients (n = 30)   Control (n = 30)
  Age (y)               69 (54--80)              66(55--77)
  Sex                                            
  Male                  25 (83.3%)               23 (76.7%)
  Female                5 (16.7%)                7 (23.3%)
  Smoking                                        
  None                  4 (13.3%)                
  Ex                    9 (30%)                  
  Current               17 (56.7%)               
  Tumor location                                 
  Ut                    6 (20%)                  
  Mt                    10 (33.3%)               
  Lt                    14 (46.7%)               
  Ae                    0                        
  Differentiation                                
  Well                  4 (13.3%)                
  Moderate              13 (43.3%)               
  Poor                  11 (36.7%)               
  Unknown               2 (6.7%)                 
  Clinical Stage                                 
  I                     10 (33.3%)               
  II                    5 (16.7%)                
  III                   11 (36.7%)               
  IVA                   1 (3.3%)                 
  IVB                   3 (10%)                  
  Treatment                                      
  ESD                   3 (10%)                  
  Surgery               15 (50%)                 
  Neoadjuvant therapy   9 (30%)                  
  CRT                   2 (6.7%)                 
  CT                    1 (3.3%)                 
  Pathological Stage                             
  IA                    5 (16.7%)                
  IB                    6 (20%%)                 
  IIA                   1 (3.3%)                 
  IIB                   6 (20%)                  
  IIIA                  2 (6.7%)                 
  IIIB                  4 (13.3%)                
  IVA                   2 (6.7%)                 
  IVB                   1 (3.3%)                 
  **C**                                          
                        ESCC patients (n = 18)   Control (n = 18)
  Age (y)               66 (38--81)              64 (32--75)
  Sex                                            
  Male                  11 (61.1%)               10 (55.6%)
  Female                7 (38.9%)                8 (44.4%)
  Smoking                                        
  None                  3 (16.7%)                
  Ex                    8 (44.4%)                
  Current               7 (38.9%)                
  Tumor location                                 
  Ut                    4(22.2%)                 
  Mt                    9 (50%)                  
  Lt                    5 (27.8%)                
  Ae                    0                        
  Differentiation                                
  Well                  2 (11.1%)                
  Moderate              9 (50%)                  
  Poor                  6 (33.3%)                
  Unknown               1 (5.6%)                 
  Clinical Stage                                 
  I                     7 (38.9%)                
  II                    3 (16.7%)                
  III                   5 (27.8%)                
  IVA                   0                        
  IVB                   3 (16.7%)                
  Treatment                                      
  ESD                   4 (22.2%)                
  Surgery               4 (22.2%)                
  Neoadjuvant therapy   8 (44.4%)                
  CRT                   0                        
  CT                    2 (11.1%)                
  Pathological Stage                             
  IA                    6 (33.3%)                
  IB                    2(11.1%)                 
  IIA                   1 (5.6%)                 
  IIB                   0                        
  IIIA                  1 (5.6%)                 
  IIIB                  4 (22.2%)                
  IVA                   0                        
  IVB                   2 (11.1%)                
  --------------------- ------------------------ ------------------

CRT, definitive chemoradiotherapy; CT, palliative chemotherapy; ESD, endoscopic submucosal dissection; Ex, ex-smoker; Lt, lower thoracic; Mt, middle thoracic; Neo, neoadjuvant chemotherapy or chemoradiotherapy; S, surgery; Ut, upper thoracic.

Among the 66 samples from patients with ESCC before treatment, 22 were collected at 1 month after treatment. Serum samples were also collected from 4 patients who experienced postoperative recurrence at the time of recurrence. Furthermore, samples were collected from patients with esophageal adenocarcinoma (EAD; n = 4) and high-grade dysplasia (HGD; n = 4) who were enrolled to assess specificity for ESCC. [Fig 1](#pone.0231116.g001){ref-type="fig"} shows overview of this study. The study was approved by the Institutional Review Board of Hiroshima University.

![Overview of this study.](pone.0231116.g001){#pone.0231116.g001}

RNA extraction from serum samples {#sec008}
---------------------------------

After obtaining informed consent, 2ml of peripheral blood was obtained from each patient before any treatment procedure.Serum was separated by centrifugation at 3000 rpm for 10 min at 4°C. The supernatant was collected into a new tube and the serum sample was stored at -80°C. Total RNA was isolated from 200 μl serum using a miRNeasy mini kit (Qiagen) according to the manufacturer\'s protocol.

cDNA library for micro RNA sequencing {#sec009}
-------------------------------------

An Ion Total RNA-Seq Kit v2 was used to prepare a reconstructive cDNA library for preparation of small RNA sequencing. The size and concentration of base pairs of the cDNA library were measured with an Agilent 2100 Bioanalyzer (Agilent Technologies). Preparation for deep sequencing such as emulsion PCR, bead enrichment, and chip loading were automatically performed on an Ion Chef− instrument (Thermo Fisher Scientific). In the final step of sample preparation for sequencing, the chip was loaded with the Ion Sphere Particle (ISP) sequencing reaction mixture. Synthesized templates were sequenced on an Ion S5−XL sequencer (Thermo Fisher Scientific) using an Ion 540− chip.

Data analysis {#sec010}
-------------

After the sequencing reaction, the data were checked for quality. We defined acceptable data as 70% or more above ISP loading density, and 60 or more templates per ISP; 30% or more usable reads, and 5% or less test fragments per total reads; and 100000 or more usable reads per sample. Acceptable data was analyzed using a CLC genomics work bench 7(CLC bio). Small RNAs were merged by count read number and annotated based on miRbase version 21 (<http://www.mirbase.org/>). IsomiRs were identified by differences such as additions or deletions compared with mature miRs. To compare the read number of small RNAs between samples, total read numbers of each sample were normalized to 1,000,000 reads; in other words, each small RNA read number was calculated per 1,000,000.

Diagnostic biomarkers were identified by analyzing normalized read numbers of miR/isomiRs between ESCC and HC using the Student t-test. As defined diagnostic biomarkers were identified in over 90% of samples of both the ESCC and HC groups, mean read numbers significantly differed more than 2-fold (p\<0.05). Candidates miR/isomiRs which met our criteria for diagnostic biomarkers were entered stepwise into a multiple linear regression model to generate a diagnostic panel for ESCC. Minimum Bayesian Information Criteria (BIC) method was applied to select the best model. A panel index was calculated by assigning the read number of candidates of miR/isomiR selected by the diagnostic panel. Receiver operating characteristic (ROC) curves of the candidate of miR/isomiRs and panel index were generated to predict ESCC patients. The panel index was compared between patients with HGD, EAD, and ESCC using the Student t-test, and between pre- and post-treatment using the paired t-test. Data are presented as numbers (%) or as mean ± standard deviation in normally distributed continuous variables. Frequencies were compared using the χ^2^ test for categorical variables and small samples were analyzed using Fisher's exact test.

All data were statistically analyzed using JMP® 14 (SAS Institute Inc., Cary, NC, USA).

Results {#sec011}
=======

Identification of diagnostic biomarkers for ESCC {#sec012}
------------------------------------------------

In the 1^st^ group, 5451 miR/isomiRs were detected in at least one sample ([S1 File](#pone.0231116.s007){ref-type="supplementary-material"}). Among these, 303 miR/isomiRs were detected in over 90% of each group. Twenty-eight mature miRs and 60 isomiRs met the criteria for diagnostic biomarkers. These 88 candidates were validated in the 2^nd^ group. The results of sequencing in the 2^nd^ group were shown in [S2 File](#pone.0231116.s008){ref-type="supplementary-material"}. As a result, 9 mature miRs and 15 isomiRs also met the criteria in the 2^nd^ group. [Table 2](#pone.0231116.t002){ref-type="table"} shows the profile of these candidates of miR/isomiRs, read number for ESCC and HC, fold change, and p-value in the 1^st^ and 2^nd^ group.

10.1371/journal.pone.0231116.t002

###### Profile of biomarker candidates of miR/isomiR.

![](pone.0231116.t002){#pone.0231116.t002g}

  Small RNA                                   L    Sequence                   1^st^ group   2^nd^ group                                                     
  ------------------------------------------- ---- -------------------------- ------------- ------------- ------ --------- ------------- ----------- ------ ---------
  miR-885-5p                                  22   `UCCAUUACACUACCCUGCCUCU`   4147±2974     169±153       24.4   \<0.001   1915±2301     119±138     16.1   \<0.001
  miR-574-3p (3' deletion A)\*                21   `CACGCUCAUGCACACACCCAC`    372±228       65±40         5.69   \<0.001   277±254       49±29       5.63   \<0.001
  miR-378a-3p                                 22   `ACUGGACUUGGAGUCAGAAGGC`   1977±2389     454±229       4.36   0.042     1158±962      360±212     3.21   \<0.001
  miR-375-3p                                  22   `UUUGUUCGUUCGGCUCGCGUGA`   598±472       95±71         6.3    0.001     618±811       97±82       6.4    0.001
  miR-365a/365b-3p                            22   `UAAUGCCCCUAAAAAUCCUUAU`   1062±804      185±167       5.73   0.001     1050±1187     310±238     3.38   0.001
  miR-335-5p (3' deletion U)\*                22   `UCAAGAGCAAUAACGAAAAAUG`   746±558       213±123       3.5    0.006     509±554       166±123     3.05   0.0015
  miR-205-5p (3' deletion G)\*                21   `UCCUUCAUUCCACCGGAGUCU`    814±508       152±142       5.36   \<0.001   1804±2567     187±177     9.62   0.0031
  miR-199a-1/a-2-3p (3' deletion A)\*         21   `ACAGUAGUCUGCACAUUGGUU`    1050±683      448±244       2.34   0.008     800±1162      362±225     2.2    0.002
  miR-193a-5p                                 22   `UGGGUCUUUGCGGGCGAGAUGA`   2321±2301     752±450       3.09   0.019     1991±1162     702±395     2.72   \<0.001
  miR-148-3p (3' deletion U)\*                21   `UCAGUGCACUACAGAACUUUG`    2593±1352     804±239       3.22   \<0.001   1946±2027     950±306     2.05   0.011
  miR-145-5p (3' deletion U)\*                22   `GUCCAGUUUUCCCAGGAAUCCC`   12103±7220    1980±2218     6.11   \<0.001   8023±9544     1809±983    4.43   \<0.001
  miR-145-5p (3' deletion CU)\*               21   `GUCCAGUUUUCCCAGGAAUCC`    5551±3534     1467±1459     3.78   0.001     5990±5976     1955±1190   3.06   \<0.001
  miR-125b-1/b-2-5p (3' deletion GA)\*        20   `UCCCUGAGACCCUAACUUGU`     1677±1448     211±152       7.92   \<0.001   1133±1295     184±133     6.13   \<0.001
  miR122-5p                                   22   `UGGAGUGUGACAAUGGUGUUUG`   15588±35076   1228±963      12.7   0.04      5694±22830    622±437     9.15   \<0.001
  miR122-5p (3' deletion G)\*                 21   `UGGAGUGUGACAAUGGUGUUU`    35663±35332   2376±1296     15     \<0.001   17822±22707   2024±1671   8.8    \<0.001
  miR122-5p (3' deletion UG)\*                20   `UGGAGUGUGACAAUGGUGUU`     1373±1488     164±122       8.3    0.011     538±596       123±141     4.34   \<0.001
  miR-99a-5p (3' deletion G)\*                21   `AACCCGUAGAUCCGAUCUUGU`    4521±3794     327±358       13.8   0.001     363±362       152±146     2.38   0.003
  miR-34a-5p                                  22   `UGGCAGUGUCUUAGCUGGUUGU`   927±713       131±95        6.97   0.001     385±229       115±77      3.18   \<0.001
  miR-30a-5p                                  22   `UGUAAACAUCCUCGACUGGAAG`   1514±824      334±159       4.53   \<0.001   1563±1034     451±377     3.46   \<0.001
  miR-27b-3p (3' deletion C)\*                20   `UUCACAGUGGCUAAGUUCUG`     701±491       191±99        3.67   0.002     640±625       178±89      3.56   \<0.001
  miR-22-3p                                   22   `AAGCUGCCAGUUGAAGAACUGU`   6665±3375     3347±1917     2      0.006     5497±2945     2707±1126   2.03   \<0.001
  miR-10b-5p (3' deletion G)\*                22   `UACCCUGUAGAACCGAAUUUGU`   1842±1069     648±296       2.99   0.003     1572±951      562±344     2.8    \<0.001
  miR-10b-5p (3' deletion GU)\*               21   `UACCCUGUAGAACCGAAUUUG`    422±290       140±71        2.84   0.001     524±308       214±142     2.45   \<0.001
  miR-10a-5p (5'deletion U, 3'deletion G)\*   21   `ACCCUGUAGAUCCGAAUUUGU`    238±45        52±14         4.54   0.001     413±167       149±42      2.77   0.004

**\*,** isomiR; ESCC, patients with esophageal squamous cell carcinoma; FC, fold change, HC, healthy control; L, length of sequence; miR, micro RNA.

Creation of the diagnostic panel {#sec013}
--------------------------------

Twenty-four candidates which met the criteria for diagnostic biomarker were entered into a multiple regression model with stepwise selection to generate diagnostic panel for ESCC. The model entered variables to forward, and judged combination of three variables as optimal; one mature miRNA (miR-30a-5p) and two isomiRs \[miR-574-3p (3' deletion A) and miR-205-5p (3' deletion G)\] ([S1 Fig](#pone.0231116.s001){ref-type="supplementary-material"} and [S3 File](#pone.0231116.s009){ref-type="supplementary-material"}). Individual read numbers of miR/isomiRs used in the diagnostic panel are shown in [Fig 2](#pone.0231116.g002){ref-type="fig"}, and their diagnostic significance is shown in [S2 Fig](#pone.0231116.s002){ref-type="supplementary-material"}. The panel index was calculated from estimates indicated by the regression model \[Panel Index = 0.83+0.015×miR-574-3p(3' deletion A)+0.004×miR-205-5p(3' deletion G)+0.0018×miR-30a-5p\]. This index was significantly higher in patients with ESCC than HC (3.1±1.3 vs. 13.3±8.9, p\<0.001). The area under the receiver operating characteristics (ROC) curves (AUC) of the panel index used to predict ESCC patients was 0.95 (95% CI, 0.91--1.0, p\<0.001; [Fig 3](#pone.0231116.g003){ref-type="fig"}). Using the optimal cut off value of 4.0, sensitivity and specificity was 93.8% and 81%, respectively ([Fig 4A](#pone.0231116.g004){ref-type="fig"}).

![Read numbers of miR/isomiRs applied to the diagnostic panel in healthy control and patients with ESCC.\
Boxplot of read numbers of miR/isomiRs applied to the diagnostic panel in healthy control and patients with ESCC; miR-574-3p (3' deletion A) (A), miR-205-5p (3' deletion G) (B), and miR-30a-5p (C).](pone.0231116.g002){#pone.0231116.g002}

![Receiver operating characteristics (ROC) curves of the panel index in the 1^st^ and 2^nd^ groups.\
Area under receiver operating characteristics curves (AUC) for panel index to predict esophageal squamous cell carcinoma: AUC, 0.95; 95% CI, 0.92--1.0; p\<0.001.](pone.0231116.g003){#pone.0231116.g003}

![Significance of the diagnostic panel.\
Mean panel index was significantly higher in patients with ESCC than HC (13.3±8.9 vs. 3.1±1.3, p\<0.001) in 1^st^ and 2^nd^ groups. Diagnostic sensitivity and specificity were 93.8% and 81%, using cut off value for the panel index of 4.0 in the 1^st^ and 2^nd^ groups (A). Mean panel index was significantly higher in patients with ESCC than HC (16.8±21.2 vs. 3.6±1.3, p\<0.001) in the 3^rd^ group. Diagnostic sensitivity and specificity were 88.9% and 72.2%, using a cut off value for the panel index of 4.0 in the 3^rd^ group (B).](pone.0231116.g004){#pone.0231116.g004}

Validating the diagnostic panel {#sec014}
-------------------------------

To confirm the diagnostic value of our panel for ESCC, we tested it in another independent group (3^rd^ group [S4 File](#pone.0231116.s010){ref-type="supplementary-material"}). Mean value of the panel index was 16.8±20.8 and 3.6±1.3 in patients with ESCC and HC, respectively (p\<0.001). Diagnostic sensitivity and specificity using same cut off value was 88.9% and 72.3% ([Fig 4B](#pone.0231116.g004){ref-type="fig"}). AUC of the ROC curve was 0.89 (95%CI, 0.78--1.0, p\<0.001; [S3 Fig](#pone.0231116.s003){ref-type="supplementary-material"}).

Comparison of panel index between patients with ESCC, EAD and HGD {#sec015}
-----------------------------------------------------------------

The profiles of miR/isomiRs were also investigated in patients with EAD and HGD ([S5 File](#pone.0231116.s011){ref-type="supplementary-material"}). The mean panel index of patients with EAD and HGD was 4.2±1.7 and 6.2±4.5, respectively. These values were significantly lower than that of patients with ESCC. In contrast, while they were also higher than in HC, the difference was not statistically significant ([Fig 5](#pone.0231116.g005){ref-type="fig"}).

![Comparison of diagnostic panel index in patients with esophageal dysplasia, adenocarcinoma and squamous cell carcinoma.\
Mean panel indices of patients with esophageal adenocarcinoma (4.2±1.7) and high-grade dysplasia (6.2±4.5) were significantly lower than patients with ESCC (14.1±13.3), but did not significantly defer compared from the HC (3.2 ± 1.3).](pone.0231116.g005){#pone.0231116.g005}

Relationship between panel index and clinical and pathological stage {#sec016}
--------------------------------------------------------------------

[Fig 6A](#pone.0231116.g006){ref-type="fig"} shows the panel index of patients with ESCC according to clinical stage. Mean panel index of patients with stage I, II, III, and IV disease was 11.4±6.3, 13.8±7.2, 12.8±11.7 and 31.2±28.9, respectively. Patients with stage IV tend to have a higher index compared with those with stage I--III disease, but the difference was not significant. A similar trend was seen by pathological stage ([Fig 6B](#pone.0231116.g006){ref-type="fig"}). While patients with clinical stage I disease tended to have a lower index than those with advanced stage disease, the index was still significantly higher than that in HCs. Diagnostic sensitivity and specificity using cut off value of 4.0 was 91.0% and 77.4%, respectively. AUC of the ROC curve was 0.93 (95%CI, 0.85--1.0, p\<0.001; [S4 Fig](#pone.0231116.s004){ref-type="supplementary-material"}).

![Comparison of diagnostic panel index according to stage.\
Patients of all stages had a significantly higher panel index than the healthy control. Panel index of patients with clinical stage IV disease (31.2±28.9) tended to be high compared with clinical stages I (11.4±6.3), II (13.8±7.2), and III (12.8±11.7), although without statistical significance (A). Panel index of patients with pathological stage IV disease (27.3±17.8) tended to be high compared with pathological stage IA (10.9±7.2), IB (12.8±6.2), II (10.9± 6.1), and III (8.8 ±6.6), although without statistical significance (B).](pone.0231116.g006){#pone.0231116.g006}

Time course of change in panel index of patients with ESCC during treatment and at recurrence {#sec017}
---------------------------------------------------------------------------------------------

The 22 paired samples at pre- and post- treatment were investigated for the expression of miR/isomiR, and a panel index was calculated. Mean panel index after treatment was significantly decreased compared with that before treatment (6.2±5.6 vs 11.6±11.5, p = 0.03; [Fig 7](#pone.0231116.g007){ref-type="fig"}) Eighteen cases (81.8%) showed a decrease in panel index after treatment compared with before. Mean decreased ratio was 0.28±0.15 ([S5 Fig](#pone.0231116.s005){ref-type="supplementary-material"}). [Fig 8](#pone.0231116.g008){ref-type="fig"} shows the time course of panel index changes in the four patients who experienced postoperative recurrence. Panel index of all four patients decreased after treatment compared with those before, and increased again at recurrence in three ([S6 Fig](#pone.0231116.s006){ref-type="supplementary-material"}).

![Comparison of panel index before and after treatment.\
Mean panel index of after treatment was significantly decreased compared with before treatment (6.2±5.6 vs 11.6±11.5, p = 0.03).](pone.0231116.g007){#pone.0231116.g007}

![Time course of panel index change ratio in patients who experienced postoperative recurrence.\
Change rate of the panel index when pre-treatment panel index is 1.0. Index decreased in all four patients after treatment compared with before, re-increased in three of four who experienced recurrence.](pone.0231116.g008){#pone.0231116.g008}

Discussion {#sec018}
----------

We aimed to identify the clinical significance of circulating miR/isomiRs in patients with ESCC detected by NGS. We identified 24 miR/isomiRs as diagnostic biomarkers by comparison between ESCC patients and HCs in different two cohorts. The diagnostic panel generated by these candidates had high accuracy in the diagnosis of ESCC.

Early detection is important in improving outcomes in patients with ESCC. Endoscopic screening is the standard for detecting superficial ESCC \[[@pone.0231116.ref023]\]. Although recent advances in diagnostic technology for cancer such as narrow band imaging provide high accuracy, the relatively low incidence of ESCC renders population-based screening ineffective. Endoscopy also causes chest discomfort in all subjects and sometimes has unpleasant adverse effects, such as aspiration pneumonia. Accordingly, screening for ESCC should be limited to individuals at high risk. In fact, screening endoscopy has been proven effective in detecting early-stage ESCC and precancerous lesions in a high-risk region in China \[[@pone.0231116.ref024]\]. However, regional differences in the occurrence of esophageal cancer are not seen in Japan or Western countries, indicating the need for biomarkers that can detect patients with ESCC. Given the low invasiveness of blood sampling, circulating small RNA might be an ideal biomarker candidate. Indeed, many studies have confirmed the usefulness of circulating miR in detecting cancer. Theoretically, isomiRs might also be powerful biomarkers, like mature miRs. However, few studies have examined this possibility, primary because the similarity in the sequences of isomiR and mature miR makes it technically difficult to distinguish them by usual quantitative polymerase chain reaction (qPCR). Recent developments in deep sequencing systems, represented by NGS, allow the detection of even slight differences in small RNAs and the identification of isomiRs. Several researchers have described studies focused on isomiRs from tumors. Wu et al reported that expression of isomiRs in colorectal tissue differed between normal mucosa, adenoma, and adenocarcinoma \[[@pone.0231116.ref025]\]. Roberts et al reported that circulating small RNA, including isomiR, were associated with colorectal adenoma \[[@pone.0231116.ref026]\]; and Mjelle et al identified circulating miR/isomiR associated with metastasis of rectal cancer \[[@pone.0231116.ref027]\]. However, few studies have examined differences in miR/isomiR between cancer patients and healthy individuals. To our knowledge, our present study is the first to show the usefulness of combination of circulating miR/somiRs detected by NGS in the diagnosis of esophageal cancer.

Our diagnostic panel was generated by comparing patients with ESCC at all stages and HC controls. The panel was useful in detecting patients even at stage I, and in distinguishing patients with ESCC from those with from HGD and EAD. These findings would also be useful in distinguishing individuals at high risk of ESCC but without significant symptoms, and in population-level endoscopy screening.

This panel includes one mature miR and two isomiRs. According to previous reports, miR-30a-5p plays a dual role in different types of cancer as either an oncogene or onco-suppressor \[[@pone.0231116.ref028]\]. Function of miR-30a-5p as cancer activators has been reported in pharyngeal cancer \[[@pone.0231116.ref029]\], ovarian cancer \[[@pone.0231116.ref030]\] and glioma \[[@pone.0231116.ref031]\]. Their expression profiles also differ between cancer and normal tissue. Kimura et al reported that miR-30a-5p is up-regulated in ESCC, as well as in a head and neck squamous cell carcinoma cell line compared with normal squamous epithelial cell lines \[[@pone.0231116.ref032]\]. In contrast, circulating miR-30a-5p is down-regulated in patients with EAD compared with healthy control \[[@pone.0231116.ref033]\]. MiR-205-5p also has several functions which appear to depend on cellular context and tumor subtype. It is also reported to have specific features in squamous cell carcinoma, and is a reliable biomarker to distinguish squamous cell carcinoma from other subtypes in non-small lung cell cancer tissue \[[@pone.0231116.ref034]--[@pone.0231116.ref036]\]. Circulating miR-205-5p is up-regulated in patients with lung squamous cell carcinoma \[[@pone.0231116.ref036]\] and cervical cancer \[[@pone.0231116.ref037]\]. Moreover, a recent study found that miR-205-5p has different function in squamous cell carcinoma and adenocarcinoma in the esophagus \[[@pone.0231116.ref038]\]. MiR-574-3p is upregulated in hepatocellular carcinoma \[[@pone.0231116.ref039]\] and prostate cancer \[[@pone.0231116.ref040]\], and is positively associated with the proliferation of osteosarcoma \[[@pone.0231116.ref041]\]. Moreover, Krishnan et al described the prognostic impact of miR-574-3p detected by NGS from breast cancer tissue \[[@pone.0231116.ref042]\].

Of note, these previous reports dealt with the mature miR-205-5p and miR-574-3p whereas our diagnostic panel included isomiR. The two types were previously thought to have a similar function because of their similar sequence, but more recent studies have identified that they have different functions \[[@pone.0231116.ref019], [@pone.0231116.ref043], [@pone.0231116.ref044]\]. In fact, the target messenger RNA of isomiR has concordance and discordance with mature miR, in accordance with the difference between them in sequence \[[@pone.0231116.ref045]\]. Further study is therefore needed to identify whether these isomiRs have the same function as mature miRs.

Although our panel is not aimed at detecting postoperative recurrence, the panel index was decreased after treatment compared with that before treatment in almost all cases, and re-increased at recurrence in three of four patients. Some miR/isomiRs likely change as a reflection of tumor volume. Supporting this, Komatsu et al reported that levels of circulating miR-25 changed before and after surgery \[[@pone.0231116.ref014]\]. Follow-up of certain miR/isomiRs by post-treatment survey might be worthwhile.

Several limitations of our study warrant mention. Because few studies have dealt with circulating miR/isomiR detected by NGS, no clear consensus exists for the normalization of miR/isomiR, nor is there a consistent method for analyzing data. We normalized read number as 1,000,000 reads per sample in accordance with a previous report. If normalization and data analysis methods change, different results will be obtained. Our results were also influenced by the number of samples assigned to each group and the method of statistical analysis. Obtaining repeatable results in future studies therefore requires establishment of a concrete consensus. External validation is preferred to confirm accuracy of our results, but it is difficult because there is no public database containing information on circulating isomiR in ESCC patients. Therefore we tested the application for our diagnostic panel using another cohort, but it was using retrospective single institution samples after all. Prospective confirmation study is needed before clinical application. We investigated miR/isomiR profiles from serum samples stored for several periods. Although there was no substantial difference between the retention periods of samples from patients and HC, the possibility that this difference affected the results cannot be denied. It remains unclear whether these candidate miR/isomiRs for diagnostic biomarkers differ between normal squamous epithelium and squamous cell carcinoma tissue, as does the function of these candidates in vivo, and further studies are needed to clarify these questions. We focused on miR/isomiR in the present study, but other small RNAs are abundant in tissue and blood and can be detected by NGS. These small RNAs might include other powerful biomarkers of ESCC.

Conclusion {#sec019}
==========

We focused on circulating miR/isomiR detected by NGS as novel biomarkers of ESCC. Our diagnostic panel had high accuracy in diagnosis and high specificity as a biomarker of ESCC. Although a number of problems must be resolved before clinical application, miR/isomiRs detected by NGS could serve as novel biomarkers of ESCC.

Supporting information {#sec020}
======================

###### Bayesian information criteria (BIC) value according to combination of variables.

The forward stepwise model showed the combination of miR-574-3p (3' deletion A), miR-205-5p (3' deletion G), and miR-30a-5p indicated the minimum BIC.

(TIF)

###### 

Click here for additional data file.

###### Diagnostic significance of miR/isomiRs used in the diagnostic panel.

Area under the receiver operating characteristics curves (AUC) for miR-574-3p (3' deletion A) (A), miR-205-5p (3' deletion G) (B), and miR-30a-5p (C) to predict esophageal squamous cell carcinoma. miR-574-3p (3' deletion A): AUC, 0.84; 95% CI, 0.75--0.93; p\<0.001; miR-205-5p (3' deletion G): AUC, 0.92; 95% CI, 0.86--0.97; p\<0.001, and miR-30a-5p: AUC, 0.89; 95% CI, 0.82--0.96; p\<0.001.

(TIF)

###### 

Click here for additional data file.

###### Receiver operating characteristics (ROC) curves of the panel index in the 3^rd^ group.

Area under the receiver operating characteristics curves (AUC) for the panel index to predict esophageal squamous cell carcinoma: AUC, 0.89; 95% CI, 0.78--1.0; p\<0.001.

(TIF)

###### 

Click here for additional data file.

###### Significance of the diagnostic panel for clinical stage I ESCC.

Area under receiver operating characteristics curves (AUC) for panel index to predict stage I esophageal squamous cell carcinoma: AUC, 0.93; 95% CI, 0.9--1.0; p\<0.001. Diagnostic sensitivity and specificity were 90.4% and 78.4%, using a cut off value for the panel index of 4.0.

(TIF)

###### 

Click here for additional data file.

###### Panel index change ratio after treatment compared with before treatment.

Change rate of the panel index when the pre-treatment panel index is 1.0. Mean post-treatment panel index was significantly decreased compared with pre-treatment (mean decrease in ratio was 0.28±0.15).

(TIF)

###### 

Click here for additional data file.

###### Comparison of panel index before, and after treatment, and at recurrence.

Time course of changes in panel index in patients who experienced post-operative recurrence.

(TIF)

###### 

Click here for additional data file.

###### Expression profile of miR/isomiR in the 1^st^ group.

(XLSX)

###### 

Click here for additional data file.

###### Expression profile of miR/isomiR in the 2^nd^ group.

(XLSX)

###### 

Click here for additional data file.

###### Stepwise regression model to generate a diagnostic panel for ESCC.

(XLSX)

###### 

Click here for additional data file.

###### Expression profile of miR/isomiR in the 3^rd^ group.

(XLSX)

###### 

Click here for additional data file.

###### Expression profile of miR/isomiR in patients with esophageal dysplasia and adenocarcinoma.

(XLSX)

###### 

Click here for additional data file.

The authors thanks Prof. Junko Tanaka (Professor of Department of Epidemiology, Infectious Disease Control and Prevention, Hiroshima university) for supervising statistical analysis.
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Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma.
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Dear Prof Tahara,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

This is a retrospective, single-institute study that examines microRNAs (miRNAs) and isomicroRNAs (isomiRs) using the next generation sequencer (NGS) in serum samples from 66 patients with esophageal squamous cell carcinoma (ESCC) designed to identify circulating miR/isomiRs that could be used as novel biomarker for ESCC. You have demonstrated that your diagnostic panel index derived from the regression analysis with miR-30a-5p and isoforms of miR-574-3p and miR-205-5p had high accuracy in the diagnosis of ESCC. You have suggested that MiR/isomiRs detected by NGS can be novel biomarkers of ESCC. 

You have demonstrated that twenty-four miRNA/isomiR candidates are entered into a multiple regression model with stepwise selection to generate diagnostic panel for ESCC. Despite your appreciable efforts with NGS, major limitation of your study is the very small number of discovery cohort to perform regression analysis. In regression analysis, 10 observations per variable are recommended. So, generation of panel index with coefficients from stepwise regression analysis is not statistically appropriate. You would be better to combine your cohorts to maximize the number of samples, which approach would be more statistically reasonable. As the independent validation of your findings, you can use publicly available ESCC cohorts from GEO and TCGA database.  

Normally distributed continuous variables are reported as mean ± standard deviation; non--normally distributed continuous variables, as median and range (or IQR).

Many grammar and typo errors are found. Thorough editing is required.

We would appreciate receiving your revised manuscript by Feb 10 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Hyun-Sung Lee, M.D., Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for stating the following in the Competing Interests section:

\"Prof. Hidetoshi Tahara is representative director of a university-originated venture, MiRTeL Co. Ltd., which provides commercial microRNA panel services. The remaining authors declare no potential conflict of interest.\"

We note that one or more of the authors are employed by a commercial company: MiRTeL Co. Ltd..

1.) Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2.) Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. 

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

3\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Some comments:

1\. There are some english errors.

2\. Spell out some words

3\. Background in the abstract should be write in better way

4\. Add the below references for the first sentence of \"Introduction section\"

a\. Int J Cancer. 2019 Mar 15;144(6):1215-1226.

b\. J Cell Physiol. 2018 Nov;233(11):8538-8550

5\. Add the below references for this sentence:

\"MicroRNA(miR)s are classified as small noncoding RNAs (19 - 25 nucleotides) which

regulate the expression of plural numbers of messenger RNAs\"

a\. J Cell Biochem. 2017 Dec;118(12):4121-4128

b\. Adv Clin Chem. 2017;82:47-70.

c\. J Cell Physiol. 2018 Feb;233(2):866-879.

Reviewer \#2: The study tried to explore the biomarkers of ESCC from the microRNA/isomiRs in circulating blood based on the technique of NGS. It is a very interesting and important study; the research was well conducted and the manuscript is well written and easy to follow. There are some specific suggestions for the revision of the paper according bellow that should help to improve the readability of the paper for the PLOS ONE audience.

1\. In this nested case-control study, the authors select almost equal number (18 vs 12, 30 vs 30, 18 vs 18) of HC individuals as the patients after the age, sex matching. As I see, the result of the first group was the most important, why the number of HC was less than the case group? How did the authors select the HC individuals? If possible, a larger sample size may been more convinced.

2\. In the 3rd group, the authors tried to test the "biomarkers" found from the two groups. Actually, to test the value of your discoveries, It seemly better to conduct a pure prospective case-control study instead of the ESCC patients only. How did the authors think?

3\. The authors should check the spellings and grammar. Such as the "sere" in line 81.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Responses to the comments of Editor

We gratefully appreciate your review our manuscript and the helpful suggestions. Our point-by-point responses to your comments and suggestions are listed below.

Comment 1

Despite your appreciable efforts with NGS, major limitation of your study is the very small number of discovery cohort to perform regression analysis. In regression analysis, 10 observations per variable are recommended. So, generation of panel index with coefficients from stepwise regression analysis is not statistically appropriate. You would be better to combine your cohorts to maximize the number of samples, which approach would be more statistically reasonable. As the independent validation of your findings, you can use publicly available ESCC cohorts from GEO and TCGA database.

Response

As suggested by the editor, limited number of samples was limitation of this study. NGS analysis is difficult to analyze many samples due to cost for now. We analyzed more than 100 samples of patients and control to discover biomarker of ESCC. This number is the largest effort ever reported included other cancer.

It is well known that different RNA extraction methods strongly affected the NGS results, and there is no public database containing information on circulating isomiR in ESCC patients. Therefore, external validation is difficult, and internal validation was proceeded by dividing samples in this study. Thus, prospective study is needed before clinical application. Therefore, we added this sentence in the documents (''We tested the application for our diagnostic panel using another cohort, but it was using retrospective single institution samples after all. Therefore, prospective confirmation study is needed before clinical application.''; line279-281).

The editor also points out about stepwise procedure. We understand there is a recommendation the number of covariates should be \"10-15 observations per variable\" as a \"guide\" for multiple regression. And we also understand there is criticism against stepwise method because there is unreproducible of variable selection and the methods select covariates without considering the clinical evaluation.

However, the \"guide\" is just reference criteria, and the suitable number of covariates will change depend on the variance and covariance of variables. Stepwise procedure is effective method to decide the suitable combination of covariates with considering the possible number of covariates and correlation between covariates, especially multicollinearity. Moreover, stepwise procedure has potential to find undiscovered confounding factors.

Therefore, we applied the covariates both of clinical important covariate and variables selected by stepwise procedure We proceeded with this analysis in consultation with a clinical statistician (Prof. Junko Tanaka; Professor of Department of Epidemiology, Infectious Disease Control and Prevention, Hiroshima university).

Comment 2

Normally distributed continuous variables are reported as mean ± standard deviation; non--normally distributed continuous variables, as median and range (or IQR).

Response

As mentioned by the editor, we changed representation of normally distributed continuous variables as mean ± standard deviation. Specifically, we changed the representation of mean read number of patients and healthy control in Table 2.

Responses to the comments of Reviewer 1

We gratefully appreciate your review our manuscript and the helpful suggestions. Our point-by-point responses to your comments and suggestions are listed below.

Comment 1, 2

1\. There are some english errors.

2\. Spell out some words

Response

As suggested by the reviewer, we reviewed the text and corrected some errors (ex. ''sere →were'' in line 79). Abbreviations of micro RNA were not unified, so they were unified as ''miR''. We have also unified the description of the supporting information in the text (ex. S1 Fig. and S1 File).

Comment 3

Background in the abstract should be write in better way

Response

As suggested by reviewer, we changed background in the abstract as following " MicroRNA (miR)s are promising diagnostic biomarkers of cancer. Recent next generation sequencer (NGS) studies have found that isoforms of micro RNA (isomiR) circulate in the bloodstream similarly to mature miRs. We hypothesized that combination of circulating miR and isomiRs detected by NGS are potentially powerful cancer biomarker. The present study aimed to investigate their application in esophageal cancer. "

Comment 4, 5

4\. Add the below references for the first sentence of \"Introduction section\"

a\. Int J Cancer. 2019 Mar 15;144(6):1215-1226.

b\. J Cell Physiol. 2018 Nov;233(11):8538-8550

5\. Add the below references for this sentence:

\"MicroRNA(miR)s are classified as small noncoding RNAs (19 - 25 nucleotides) which regulate the expression of plural numbers of messenger RNAs\"

a\. J Cell Biochem. 2017 Dec;118(12):4121-4128

b\. Adv Clin Chem. 2017;82:47-70.

c\. J Cell Physiol. 2018 Feb;233(2):866-879.

Response

As suggested by the reviewer, we added these literatures in References part.

Responses to the comments of Reviewer 2

We gratefully appreciate your review our manuscript and the helpful suggestions. Our point-by-point responses to your comments and suggestions are listed below.

Comment 1

In this nested case-control study, the authors select almost equal number (18 vs 12, 30 vs 30, 18 vs 18) of HC individuals as the patients after the age, sex matching. As I see, the result of the first group was the most important, why the number of HC was less than the case group? How did the authors select the HC individuals? If possible, a larger sample size may been more convinced.

Response

One of the main reasons is that time duration of blood collection was the same between patients and controls. As the reviewers mentioned, the first group result was important. We tried to get many candidates and validate them with many patients and controls to get precise diagnostic biomarkers. In our comparative analysis method, a smaller number of samples would yield more candidates. For this reason, more numbers of samples were allocated to the second group than to the first group.

We proceeded with this analysis in consultation with a clinical statistician (Junko Tanaka; Professor of Department of Epidemiology, Infectious Disease Control and Prevention, Hiroshima university).

Comment 2

In the 3rd group, the authors tried to test the "biomarkers" found from the two groups. Actually, to test the value of your discoveries, It seemly better to conduct a pure prospective case-control study instead of the ESCC patients only. How did the authors think?.

Response

We think that prospective case-control testing is necessary for clinical use as pointed out by the reviewers. We did internal validation instead of prospective study. It is the limitations of this study. We will be conducting a prospective study based on results of the current study.

We added following the following statements to line 270-272 ''We tested the application for our diagnostic panel using another cohort, but it was using retrospective single institution samples after all. Therefore, prospective confirmation study is needed before clinical application.''

Comment 3

The authors should check the spellings and grammar. Such as the "sere" in line 81.

Response

As suggested by the reviewer, we reviewed the text and corrected some errors including in line 79. Abbreviations of micro RNA were not unified, so they were unified as ''miR''. We have also unified the description of the supporting information in the text (ex. S1 Fig. and S1 File).

10.1371/journal.pone.0231116.r003
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Dear Prof Tahara,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

You addressed statistical issues well after discussing your biostatistician. However, we are still worrying about overfitting issue from multivariable analysis with the small number of cohort. Our biostatistician recommends to build the model with n=30+30 as a discovery and then to validate with the smaller dataset. As for me, identification itself of circulating microRNA/isomiRs from enough number of samples can be acceptable without validation. Since you have performed pricey experiments with valuable human samples, more reasonable analysis would make your findings more convincing.

However, I know it would be very challenging to reanalyze all your data. Therefore, I recommend that the statistical issue should be described as the limitation of your study. Further, you would be better to provide a table to clarify the process of multivariable stepwise selection of your candidates.

We would appreciate receiving your revised manuscript by Apr 17 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Hyun-Sung Lee, M.D., Ph.D.

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)
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Responses to the comments of Editor.

We gratefully appreciate your review our manuscript and the helpful suggestions. Our point-by-point responses to your comments and suggestions are listed below.

Comment 1

I recommend that the statistical issue should be described as the limitation of your study.

As suggested by the editor, we also think that the method of statistics needs discussion. We appreciate you for accepting our method. Our laboratory is currently preparing for a prospective validation. We hope to report this result in the future. The following description has been added to the Discussion part. (''Our results were also influenced by the number of samples assigned to each group and the method of statistical analysis.''; line270-272 and ''External validation is preferred to confirm accuracy of our results, but it is difficult because there is no public database containing information on circulating isomiR in ESCC patients. Therefore we tested the application for our diagnostic panel using another cohort, but it was using retrospective single institution samples after all. Prospective confirmation study is needed before clinical application.'').

Comment 2

Further, you would be better to provide a table to clarify the process of multivariable stepwise selection of your candidates.

As suggested by the editor, we described selection method of variables for the Stepwise model in Material and methods part, and shown their results in Results part. These results are also shown in S1 Fig. and S3 File.
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Dear Dr. Tahara,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Hyun-Sung Lee, M.D., Ph.D.

Academic Editor

PLOS ONE
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Dear Dr. Tahara:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Hyun-Sung Lee

Academic Editor
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